newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 Cash, cash equivalents and marketable securities of $82.1 million as of...